Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 36

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 36
---
 to determine the Minimum Price applicable to the exercise of such February 2025 Common Warrants. The issuance of Common Stock upon the exercise of the February 2025 Common Warrants at such exercise price would result in the investors in the February 2025 Registered Direct Offering (the “February 2025 Investors”) acquiring more than 20% of the amount of Common Stock issued and outstanding prior to the February 2025 Registered Direct Offering at a price below the Minimum Price. Accordingly, the Company needs stockholder approval of the issuance of shares of Common Stock upon the exercise of the February 2025 Common Warrants. On the Record Date, assuming the issuance of all shares of Common Stock upon the exercise of all of the February 2025 Common Warrants, the February 2025 Investors would own approximately 5,102,040shares of Common Stock, assuming continued ownership of the shares of Common Stock acquired thereby in the February 2025 Registered Direct Offering and/or pursuant to exercises of Pre -FundedWarrants (as defined below), but excluding any securities acquired other than through such February 2025 Registered Direct Offering. Such shares would constitute approximately 36.6% of the then -outstandingCommon Stock after the issuance of such shares. In addition, under the terms of the February 2025 Common Warrants, an Investor may not exercise the February 2025 Common Warrants to the extent (but only to the extent) such Investor or any of its affiliates would beneficially own a number of shares of Common Stock which would exceed 4.99%, or, at the election of the Investor, a number of shares of Common Stock which would exceed 9.99%. 17

February 2025 Registered Direct Offering In February 2025, the Company consummated the February 2025 Registered Direct Offering of 300,000shares of Common Stock, 2,251,020 pre -fundedwarrants to purchase shares of Common Stock at an exercise price of $0.0001 per share (“Pre -FundedWarrants”) and 2,551,020 February 2025 Common Warrants, pursuant to the Securities Purchase Agreement, dated February 5, 2025, by and among the Company and certain Investors, for aggregate cash proceeds to the Company of approximately $5 million. Description of Securities See “ Description of Capital Stock” for a description of the Pre -FundedWarrants and February 2025 Common Warrants. Impact on Stockholders of Approval or Disapproval of